Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Identifieur interne : 000308 ( Main/Exploration ); précédent : 000307; suivant : 000309Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Auteurs : Leo F. Buckley [États-Unis] ; Judy W M. Cheng [États-Unis] ; Akshay Desai [États-Unis]Source :
- Journal of cardiovascular pharmacology [ 1533-4023 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antagonistes des récepteurs aux angiotensines (pharmacologie), Antagonistes des récepteurs des minéralocorticoïdes (pharmacologie), Betacoronavirus (isolement et purification), Humains (MeSH), Infections à coronavirus (physiopathologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie), Maladies cardiovasculaires (physiopathologie), Maladies cardiovasculaires (traitement médicamenteux), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Phénomènes physiologiques cardiovasculaires (MeSH), Pneumopathie virale (physiopathologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Système rénine-angiotensine (effets des médicaments et des substances chimiques).
- MESH :
- effets des médicaments et des substances chimiques : Système rénine-angiotensine.
- isolement et purification : Betacoronavirus.
- métabolisme : Peptidyl-Dipeptidase A.
- pharmacologie : Antagonistes des récepteurs aux angiotensines, Antagonistes des récepteurs des minéralocorticoïdes, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- physiopathologie : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Animaux, Humains, Pandémies, Phénomènes physiologiques cardiovasculaires.
English descriptors
- KwdEn :
- Angiotensin Receptor Antagonists (pharmacology), Angiotensin-Converting Enzyme Inhibitors (pharmacology), Animals (MeSH), Betacoronavirus (isolation & purification), Cardiovascular Diseases (drug therapy), Cardiovascular Diseases (physiopathology), Cardiovascular Physiological Phenomena (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Coronavirus Infections (virology), Humans (MeSH), Mineralocorticoid Receptor Antagonists (pharmacology), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (drug therapy), Pneumonia, Viral (physiopathology), Pneumonia, Viral (virology), Renin-Angiotensin System (drug effects).
- MESH :
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Mineralocorticoid Receptor Antagonists.
- drug effects : Renin-Angiotensin System.
- drug therapy : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- physiopathology : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Animals, Cardiovascular Physiological Phenomena, Humans, Pandemics.
Abstract
Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.
DOI: 10.1097/FJC.0000000000000840
PubMed: 32301766
PubMed Central: PMC7219856
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.</title><author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Services, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Services, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Practice, MCPHS University, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Practice, MCPHS University, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32301766</idno><idno type="pmid">32301766</idno><idno type="doi">10.1097/FJC.0000000000000840</idno><idno type="pmc">PMC7219856</idno><idno type="wicri:Area/Main/Corpus">000355</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000355</idno><idno type="wicri:Area/Main/Curation">000355</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000355</idno><idno type="wicri:Area/Main/Exploration">000355</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.</title><author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Services, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Services, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacy Practice, MCPHS University, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Pharmacy Practice, MCPHS University, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of cardiovascular pharmacology</title><idno type="eISSN">1533-4023</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (pharmacology)</term><term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term><term>Animals (MeSH)</term><term>Betacoronavirus (isolation & purification)</term><term>Cardiovascular Diseases (drug therapy)</term><term>Cardiovascular Diseases (physiopathology)</term><term>Cardiovascular Physiological Phenomena (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (physiopathology)</term><term>Coronavirus Infections (virology)</term><term>Humans (MeSH)</term><term>Mineralocorticoid Receptor Antagonists (pharmacology)</term><term>Pandemics (MeSH)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (virology)</term><term>Renin-Angiotensin System (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antagonistes des récepteurs aux angiotensines (pharmacologie)</term><term>Antagonistes des récepteurs des minéralocorticoïdes (pharmacologie)</term><term>Betacoronavirus (isolement et purification)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (physiopathologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie)</term><term>Maladies cardiovasculaires (physiopathologie)</term><term>Maladies cardiovasculaires (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Phénomènes physiologiques cardiovasculaires (MeSH)</term><term>Pneumopathie virale (physiopathologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Système rénine-angiotensine (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Mineralocorticoid Receptor Antagonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Renin-Angiotensin System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Système rénine-angiotensine</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cardiovascular Physiological Phenomena</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Pandémies</term><term>Phénomènes physiologiques cardiovasculaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32301766</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4023</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Journal of cardiovascular pharmacology</Title><ISOAbbreviation>J. Cardiovasc. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.</ArticleTitle><Pagination><MedlinePgn>526-529</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/FJC.0000000000000840</ELocationID><Abstract><AbstractText>Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Leo F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Judy W M</ForeName><Initials>JWM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy Practice, MCPHS University, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Pharmacol</MedlineTA><NlmUniqueID>7902492</NlmUniqueID><ISSNLinking>0160-2446</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002320" MajorTopicYN="N">Cardiovascular Physiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000451" MajorTopicYN="N">Mineralocorticoid Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32301766</ArticleId><ArticleId IdType="doi">10.1097/FJC.0000000000000840</ArticleId><ArticleId IdType="pmc">PMC7219856</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name></region><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32301766
|texte= Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32301766" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |